The European biotechnology industry continues to grow each year. The industrial biotech (IB) value chain alone generates nearly half a million jobs and €31 billion in added value in Europe. And according to EY, European financing only in the healthcare biotech area increased to $17.7 billion in 2016 (up 87% from 2015’s previous best-ever $9.5 billion total capital) and represented Europe’s fifth straight growth year (surpassing the earlier 15-year average of $4.8 billion).
- European financing only in the healthcare biotech area increased to $17.7 billion in 2016, up 87% from 2015’s previous best-ever $9.5 billion total capital.
- 2016 was Europe’s fifth straight financing growth year, surpassing the earlier 15-year average of $4.8 billion.
EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. EuropaBio represents 77 corporate and associate members and bio regions, and 15 national biotechnology associations in turn representing over 1800 biotech SMEs.
EuropaBio’s primary focus is Europe but because of the global character of the business, we also represent our members in transatlantic and worldwide discussions. We are actively engaged in increasing communications surrounding the benefits of biotech and contribute to the creation of a coherent and positive innovation climate for the bioindustry in Europe.
Through its member associations, EuropaBio fosters a standing open and transparent dialogue and communications with all stakeholders.
Value of Healthcare Biotech From Patent to Patient: The Importance of IP Rewards and Incentives
To better understand the importance of IP rewards and incentives, EuropaBio conducted a survey among a cross section of key stakeholders, such as small and medium sized enterprises (SMEs) and venture capitalists involved in the healthcare biotechnology community. This report summarizes the findings of the EuropaBio survey and provides supplementary information on the value of IP rewards and incentives and for the healthcare biotechnology industry.See Publication
The Green G-Nome’s Guide to GM Crops & Policies in the EU
The Green G-Nome is ready to guide you to new heights of knowledge about GM crops. This new guide is a must read for anyone wanting to understand the role and untapped potential of GM crops in Europe.See Publication
EuropaBio Mid-Term Alert to the EU Commission, Parliament and Council
How the EU should put innovation friendly policies back at the heart of their agenda.See Publication
Achieving the Potential of Genome Editing
EuropaBio’s paper brings the latest views from the developers and users of genome editing tools and applications. This paper seeks to support the ongoing discussion about how to increase the public understanding of these tools and the solutions that come with them, as well as how to best develop any needed regulatory policies to enable their potential.See Publication